文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Dynamics and Half-Life of Cell-Free DNA After Exercise: Insights from a Fragment Size-Specific Measurement Approach.

作者信息

Yamamoto Ryutaro, Asano Hiroshi, Tamaki Ryo, Saito Yoshihiro, Hosokawa Ami, Watari Hidemichi, Umazume Takeshi

机构信息

Department of Obstetrics, Hokkaido University Hospital, Sapporo 060-8648, Japan.

出版信息

Diagnostics (Basel). 2025 Jan 4;15(1):109. doi: 10.3390/diagnostics15010109.


DOI:10.3390/diagnostics15010109
PMID:39795637
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11720216/
Abstract

Cell-free DNA (cfDNA) is present in healthy individuals but is elevated in those undergoing physical exertion, trauma, sepsis, and certain cancers. Maintaining cfDNA concentrations is vital for immune homeostasis and preventing inflammatory responses. Understanding cfDNA release and clearance is essential for using cfDNA as a biomarker in clinical diagnostics. We focused on the fragment size of cfDNA and investigated cfDNA dynamics and half-life, particularly the 100-250 base pair fragments. : Healthy, adult men ( = 5; age 40 ± 4.1 years) were subjected to a 30 min treadmill exercise. Blood samples were collected at 0, 5, 10, 15, 30, and 60 min post-exercise using PAXgene Blood ccfDNA tubes to stabilize and prevent nuclease-mediated cfDNA degradation and minimize genomic DNA contamination risk. The cfDNA concentration was measured using an electrophoresis-based technique (4150 TapeStation system) to quantify the concentration based on cfDNA fragment size. : The results showed a cfDNA half-life of 24.2 min, with a transient increase in 100-250 base pair cfDNA fragments post-exercise, likely due to nuclease activity. These levels rapidly reverted to the baseline within an hour. : The rapid clearance of cfDNA underscores its potential as a biomarker for real-time disease monitoring and the evaluation of treatment efficacy. This study is expected to standardize cfDNA investigations, enhancing diagnosis and treatment monitoring across various disease conditions.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8137/11720216/638ef31fa744/diagnostics-15-00109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8137/11720216/64c4326f0a78/diagnostics-15-00109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8137/11720216/638ef31fa744/diagnostics-15-00109-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8137/11720216/64c4326f0a78/diagnostics-15-00109-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8137/11720216/638ef31fa744/diagnostics-15-00109-g002.jpg

相似文献

[1]
Dynamics and Half-Life of Cell-Free DNA After Exercise: Insights from a Fragment Size-Specific Measurement Approach.

Diagnostics (Basel). 2025-1-4

[2]
Cell-free DNA release under psychosocial and physical stress conditions.

Transl Psychiatry. 2018-10-29

[3]
Circulating cell-free DNA: an up-coming molecular marker in exercise physiology.

Sports Med. 2012-7-1

[4]
Pre-analytical pitfalls: How blood collection tubes influence exercise-induced cell-free DNA concentrations.

Exp Physiol. 2025-3-3

[5]
Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.

Sci Rep. 2021-3-3

[6]
Chimeric External Control to Quantify Cell Free DNA in Plasma Samples by Real Time PCR.

Avicenna J Med Biotechnol. 2016

[7]
Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples.

Clin Chem Lab Med. 2020-3-28

[8]
Exploring the Potential of Cell-Free-DNA Measurements After an Exhaustive Cycle-Ergometer Test as a Marker for Performance-Related Parameters.

Int J Sports Physiol Perform. 2017-5

[9]
Analysis of a cell-free DNA-based cancer screening cohort links fragmentomic profiles, nuclease levels, and plasma DNA concentrations.

Genome Res. 2025-1-22

[10]
High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments.

Clin Epigenetics. 2021-10-20

引用本文的文献

[1]
GeneBits: ultra-sensitive tumour-informed ctDNA monitoring of treatment response and relapse in cancer patients.

J Transl Med. 2025-8-27

[2]
Circulating-free DNA: A promising tool for early detection of myocardial infarction.

Int J Cardiol Cardiovasc Risk Prev. 2025-8-5

[3]
Design, Development, and Clinical Validation of a Novel Kit for Cell-Free DNA Extraction.

Diagnostics (Basel). 2025-7-29

[4]
Maternal Cell-Free DNA Analysis in a Fetus Affected by Beckwith-Wiedemann Syndrome: Potential for Prenatal Diagnosis.

Cureus. 2025-4-13

[5]
Pre-analytical pitfalls: How blood collection tubes influence exercise-induced cell-free DNA concentrations.

Exp Physiol. 2025-3-3

本文引用的文献

[1]
Cell-Free DNA in the Pathogenesis and Therapy of Non-Infectious Inflammations and Tumors.

Biomedicines. 2022-11-8

[2]
Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis.

Front Oncol. 2022-7-20

[3]
Feasibility of Cell-Free DNA Measurement from the Earlobe during Physiological Exercise Testing.

Diagnostics (Basel). 2022-6-2

[4]
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N Engl J Med. 2022-5-26

[5]
Sparsely methylated mitochondrial cell free DNA released from cardiomyocytes contributes to systemic inflammatory response accompanied by atrial fibrillation.

Sci Rep. 2021-3-18

[6]
The main sources of circulating cell-free DNA: Apoptosis, necrosis and active secretion.

Crit Rev Oncol Hematol. 2021-1

[7]
Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows-Venous Whole Blood and Plasma.

Curr Pathobiol Rep. 2018

[8]
Fetal fraction evaluation in non-invasive prenatal screening (NIPS).

Eur J Hum Genet. 2018-9-25

[9]
Sequencing of Circulating Cell-free DNA during Pregnancy.

N Engl J Med. 2018-8-2

[10]
Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases.

Expert Rev Mol Med. 2018-1-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索